Policy Statement

Analysis of the optic nerve (retinal nerve fiber layer) in the diagnosis and evaluation of patients with glaucoma or glaucoma suspects may be considered medically necessary when using any of the following techniques:

- Optical coherence tomography (OCT)
- Scanning laser ophthalmoscopy
- Scanning laser polarimetry (SLP)

The measurement of ocular blood flow, pulsatile ocular blood flow, or blood flow velocity is considered investigational in the diagnosis and follow-up of patients with glaucoma.

Policy Guidelines

This policy addresses techniques used to evaluate for glaucoma and does not address other ophthalmic conditions.

Coding

There is a CPT code for scanning computerized imaging of the optic nerve in the posterior segment:

- 92133: Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve

The following category III CPT code is for measurement of ocular blood flow by repetitive ocular blood flow measurement:

- 0198T: Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report

Description

Several techniques have been developed to measure the thickness of the optic nerve and retinal nerve fiber layer as a method to diagnose glaucoma. Measurement of ocular blood flow is also being evaluated as a diagnostic tool for glaucoma.

Related Policies

- Optical Coherence Tomography of the Anterior Eye Segment

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program (FEP)) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these
instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

### Regulatory Status

A number of CSLO, SLP, and OCT devices have been cleared by the U.S. Food and Drug Administration (FDA) through the 510(k) process for imaging the posterior eye segment. For example, the RTVue XR OCT Avanti™ (Optovue) is an OCT system indicated for the in vivo imaging and measurement of the retina, RNFL, and optic disc as a tool and aid in the clinical diagnosis and management of retinal diseases. The RTVue XR OCT Avanti™ with Normative Database is a quantitative tool for comparing retina, RNFL, and optic disc measurements in the human eye with a database of known normal subjects. It is intended as a diagnostic device to aid in the detection and management of ocular diseases. In 2016, the RTVue XR OCT and Avanti™ with AngioVue™ Software was cleared by the FDA through the 510(k) process (K153080) as an aid in the visualization of vascular structures of the retina and choroid. FDA product code: HLI, OBO.

In 2012, the iExaminer™ (Welch Allyn) was cleared for marketing by the FDA through the 510(k) process. The iExaminer™ consists of a hardware adapter and associated software (iPhone® App) to capture, store, send, and retrieve images from the PanOptic™ Ophthalmoscope (Welch Allyn) using an iPhone. FDA product code: HKI.

#### Table 1. Ocular Imaging Devices Cleared by the US Food and Drug Administration

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k) No.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>RESCAN 700 CALLISTO eye</td>
<td>Carl Zeiss Meditec AG</td>
<td>1/11/2019</td>
<td>K180229</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Retina Workplace</td>
<td>Carl Zeiss Meditec Inc</td>
<td>10/24/2018</td>
<td>K182318</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA+OCT and variants with High Magnification Module</td>
<td>Heidelberg Engineering GmbH</td>
<td>10/18/2018</td>
<td>K182569</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA+OCT and variants with OCT Angiography Module</td>
<td>Heidelberg Engineering GmbH</td>
<td>9/13/2018</td>
<td>K181594</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA+OCT and variants</td>
<td>Heidelberg Engineering GmbH</td>
<td>8/30/2018</td>
<td>K173648</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Image Filing Software NAVIS-EX</td>
<td>Nidek Co. Ltd</td>
<td>7/19/2018</td>
<td>K181345</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Avanti</td>
<td>Optovue Inc.</td>
<td>6/8/2018</td>
<td>K180660</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>P200TE</td>
<td>Optos plc</td>
<td>2/28/2018</td>
<td>K173707</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>DRI OCT Triton</td>
<td>Topcon plc</td>
<td>1/19/2018</td>
<td>K173119</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>IMAGEnet 6 Ophthalmic Data System</td>
<td>Topcon Corporation</td>
<td>11/1/2017</td>
<td>K171370</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA + OCT and variants</td>
<td>Heidelberg Engineering GmbH</td>
<td>11/1/2017</td>
<td>K172649</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>PRIMUS</td>
<td>Carl Zeiss Suzhou Co. Ltd.</td>
<td>6/21/2017</td>
<td>K163195</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
</tbody>
</table>
Ophthalmologic Techniques That Evaluate the Posterior Segment for Glaucoma

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k) No.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retina Workplace</td>
<td>Carl Zeiss Meditec AG</td>
<td>6/21/2017</td>
<td>K170638</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>iVue</td>
<td>Optovue Inc.</td>
<td>6/9/2017</td>
<td>K163475</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>3D OCT-1 Maestro</td>
<td>Topcon Corporation</td>
<td>3/3/2017</td>
<td>K170164</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>EnFocus 2300</td>
<td>Biotigen Inc.</td>
<td>12/9/2017</td>
<td>K162783</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>PLEX Elite 9000 SS-OCT</td>
<td>CARL ZEISS MEDITEC INC.</td>
<td>10/26/2016</td>
<td>K161194</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>3D OCT-1 Maestro</td>
<td>Topcon Corporation</td>
<td>7/28/2016</td>
<td>K161509</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>LSFG-NAVI</td>
<td>Softcare Co. Ltd.</td>
<td>5/12/2016</td>
<td>K153239</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA + OCT and variants (e.g., Spectralis FA-OCT Spectralis ICGA-OCT Spectralis OCT Blue Peak Spectralis OCT Multicolor)</td>
<td>Heidelberg Engineering GmbH</td>
<td>5/6/2016</td>
<td>K152205</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>RTVue XR OCT Avanti with AngioVue Software</td>
<td>OPTOVUE INC.</td>
<td>2/11/2016</td>
<td>K153080</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>EnFocus 2300</td>
<td>BIOPTIGEN INC.</td>
<td>12/2/2015</td>
<td>K150722</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Optical Coherence Tomography</td>
<td>CARL ZEISS MEDITEC INC.</td>
<td>9/1/2015</td>
<td>K150977</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>OCT-Camera</td>
<td>OptoMedical Technologies GmbH</td>
<td>3/4/2015</td>
<td>K142953</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>RESCAN 700</td>
<td>CARL ZEISS MEDITEC AG</td>
<td>11/18/2014</td>
<td>K141844</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>PROPPER INSIGHT</td>
<td>PROPPER MANUFACTURING CO. INC.</td>
<td>9/17/2014</td>
<td>K141638</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>CENTERVUE MACULAR INTEGRITY ASSESSMENT ENT</td>
<td>CENTERVUE SPA</td>
<td>4/23/2014</td>
<td>K133758</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>AMICO DH-W35</td>
<td>AMICO DIAGNOSTIC INCORPORATED</td>
<td>3/26/2014</td>
<td>K131939</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>IVUE 500</td>
<td>OPTOVUE INC.</td>
<td>3/19/2014</td>
<td>K133892</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>RS-3000 ADVANCE</td>
<td>NIDKE CO. LTD.</td>
<td>2/19/2014</td>
<td>K132323</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
</tbody>
</table>

**Rationale**

**Background**

Glaucoma is characterized by degeneration of the optic nerve (optic disc). Elevated intraocular pressure (IOP) has long been thought to be the primary etiology, but the relation between IOP and optic nerve damage varies among patients, suggesting a multifactorial origin. For example, some patients with clearly elevated IOP will show no optic nerve damage, while others with marginal or no pressure elevation will show optic nerve damage. The association between glaucoma and other vascular disorders (e.g., diabetes, hypertension) suggests vascular factors...
may play a role in glaucoma. Specifically, it has been hypothesized that reductions in blood flow to the optic nerve may contribute to the visual field defects associated with glaucoma.

**Diagnosis and Management**

A comprehensive ophthalmologic exam is required for the diagnosis of glaucoma, but no single test is adequate to establish diagnosis. A comprehensive ophthalmologic examination includes assessment of the optic nerve, evaluation of visual fields, and measurement of ocular pressure. The presence of characteristic changes in the optic nerve or abnormalities in visual field, together with increased IOP, is insufficient for a definitive diagnosis. However, some patients will show ophthalmologic evidence of glaucoma with normal IOPs. These cases of normal tension glaucoma are considered to be a type of primary open-angle glaucoma. Angle-closure glaucoma is another type of glaucoma associated with an increase in IOP. The increased IOP in angle-closure glaucoma arises from a reduction in aqueous outflow from the eye due to a closed angle in the anterior chamber. Diagnosis of angle-closure glaucoma is detailed in Blue Shield of California Medical Policy: Optical Coherence Tomography of the Anterior Eye Segment.

Conventional management of patients with glaucoma principally involves drug therapy to control elevated IOPs, and serial evaluation of the optic nerve, to follow disease progression. Standard methods of evaluation include careful direct examination of the optic nerve using ophthalmoscopy or stereophotography, or evaluation of visual fields. There is interest in developing more objective, reproducible techniques both to document optic nerve damage and to detect early changes in the optic nerve and retinal nerve fiber layer (RNFL) before the development of permanent visual field deficits. Specifically, evaluating changes in RNFL thickness has been investigated as a technique to diagnose and monitor glaucoma. However, IOP reduction is not effective in decreasing disease progression in a significant number of patients, and in patients with normal tension glaucoma, there is never an increase in IOP. It has been proposed that vascular dysregulation is a significant cause of damage to the RNFL, and there is interest in measuring ocular blood flow as both a diagnostic and a management tool for glaucoma. Changes in blood flow to the retina and choroid may be particularly relevant for diagnosis and treatment of normal tension glaucoma. A variety of techniques have been developed, as described below. (Note: This evidence review only addresses techniques related to the evaluation of the optic nerve, RNFL, or blood flow to the retina and choroid in patients with glaucoma.)

**Techniques to Evaluate the Optic Nerve and RNFL**

**Confocal Scanning Laser Ophthalmoscopy**

Confocal scanning laser ophthalmoscopy (CSLO) is an image acquisition technique intended to improve the quality of the eye examination compared with standard ophthalmologic examination. A laser is scanned across the retina along with a detector system. Only a single spot on the retina is illuminated at any time, resulting in a high-contrast image of great reproducibility that can be used to estimate RNFL thickness. In addition, this technique does not require maximal mydriasis, which may be problematic in patients with glaucoma. The Heidelberg Retinal Tomograph is a commonly used technology.

**Scanning Laser Polarimetry**

The RNFL is birefringent (or biorefractive), meaning that it causes a change in the state of polarization of a laser beam as it passes. A 780-nm diode laser is used to illuminate the optic nerve. The polarization state of the light emerging from the eye is then evaluated and correlated with RNFL thickness. Unlike CSLO, scanning laser polarimetry (SLP) can directly measure the thickness of the RNFL. GDx is a common SLP device. GDx contains a normative database and statistical software package that compare scan results with age-matched normal subjects of the same ethnic origin. The advantages of this system are that images can be obtained without pupil dilation and evaluation can be completed in 10 minutes. Current instruments have added enhanced and variable corneal compensation technology to account for corneal polarization.
Optical Coherence Tomography
Optical coherence tomography (OCT) uses near-infrared light to provide direct cross-sectional measurement of the RNFL. The principles employed are similar to those used in B-mode ultrasound except light, not sound, is used to produce the 2-dimensional images. The light source can be directed into the eye through a conventional slit-lamp biomicroscope and focused onto the retina through a typical 78-diopter lens. This system requires dilation of the patient's pupil. OCT analysis software is being developed to include optic nerve head parameters with spectral domain OCT, analysis of macular parameters, and hemodynamic parameters with Doppler OCT and OCT angiography.

Pulsatile Ocular Blood Flow
The pulsatile variation in ocular pressure results from the flow of blood into the eye during cardiac systole. Pulsatile ocular blood flow can thus be detected by the continuous monitoring of IOP. The detected pressure pulse can then be converted into a volume measurement using the known relation between ocular pressure and ocular volume. Pulsatile blood flow is primarily determined by the choroidal vessels, particularly relevant to patients with glaucoma, because the optic nerve is supplied in large part by choroidal circulation.

Techniques to Measure Ocular Blood Flow
A number of techniques have been developed to assess ocular blood flow. They include laser speckle flowgraphy, color Doppler imaging, Doppler Fourier domain OCT, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, and retinal functional imaging.

Laser Speckle Flowgraphy
Laser speckle is detected when a coherent light source such as laser light is dispersed from a diffusing surface such as retinal and choroidal vessels and the circulation of the optic nerve head. The varying patterns of light can be used to determine red blood cell velocity and retinal blood flow. However, due to differences in the tissue structure in different eyes, flux values cannot be used for comparisons between eyes. This limitation may be overcome by subtracting background choroidal blood flow results from the overall blood flow results in the region of interest.

Color Doppler Imaging
Color Doppler imaging has also been investigated as a technique to measure blood flow velocity in the retina and choroidal arteries. This technique delivers ultrasound in pulsed Doppler mode with a transducer set on closed eyelids. The examination takes 30 to 40 minutes, and is most effective for the mean velocity of large ophthalmic vessels such as the ophthalmic artery, the central retinal artery, and the short posterior ciliary arteries. However, total blood flow cannot be determined with this technique, and imaging is highly dependent on probe placement.

Doppler Fourier Domain OCT
Doppler Fourier domain in OCT is a noncontact imaging technique that detects the intensity of the light scattered back from erythrocytes as they move in the vessels of the ocular tissue. This induces a frequency shift that represents the velocity of the blood in the ocular tissue.

Laser Doppler Velocimetry
Laser Doppler velocimetry compares the frequency of reflected laser light from a moving particle with stationary tissue.

Confocal Scanning Laser Doppler Flowmetry
Confocal scanning laser Doppler flowmetry combines laser Doppler flowmetry with confocal scanning laser tomography. Infrared laser light is used to scan the retina, and the frequency and amplitude of Doppler shifts are determined from the reflected light. Determinations of blood velocity and blood volume are used to compute the total blood flow and create a physical map of retinal flow values.
Literature Review
Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

The use of various techniques of retinal nerve fiber layer (RNFL) analysis (confocal scanning laser ophthalmoscopy [CSLO], scanning laser polarimetry [SLP], optical coherence tomography [OCT]) for the diagnosis and management of glaucoma was addressed by 2 Blue Cross Blue Shield Association Technology Evaluation Center (TEC) Assessments (2001, 2003).2,3

Imaging of the Optic Nerve and RNFL
Clinical Context and Test Purpose
The diagnosis and monitoring of optic nerve damage are essential for evaluating the progression of glaucoma and determining appropriate treatment.

The question addressed in this evidence review is: Do imaging techniques for the optic nerve and RNFL improve diagnosis and monitoring of glaucoma?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant populations are patients with glaucoma or who are suspected to have glaucoma and are being evaluated for diagnosis and monitoring of glaucoma progression.

Interventions
The tests being considered for assessment of the optic nerve and RNFL include CSLO, SLP, and OCT. These tests are considered add-on to the standard clinical evaluation.

Comparators
There is no single criterion standard for the diagnosis of glaucoma. This diagnosis is made from a combination of visual field testing, intraocular pressure (IOP) measurement, and optic nerve and RNFL assessment by an ophthalmologist.

Outcomes
Relevant outcomes include the clarity of the images and how reliable the test is at evaluating the optic nerve and nerve fiber layer changes. Demonstration that the information can be used to improve patient outcomes is essential for determining the utility of an imaging technology. Although direct evidence on the impact of the imaging technology from controlled trials would be preferred, in most cases, a chain of evidence needs to be constructed to determine whether there is a tight linkage between the technology and improved health outcomes. The outcomes relevant to this evidence review are IOP, loss of vision, and changes in IOP-lowering medications used to treat glaucoma.

Timing
For patients with manifest glaucoma, the relevant period of follow-up is the immediate diagnosis of glaucoma. For patients with suspected glaucoma, longer term follow-up would be needed to detect changes in visual field or RNFL. Clinical utility might be demonstrated by a change in the management and reduction in glaucoma progression across follow-up.
Setting
Patients may be self-referred, referred by optometrists, or referred by a general ophthalmologist to a glaucoma specialist. These procedures can be performed in an ophthalmologist's office.

Simplifying Test Terms
There are 3 core characteristics for assessing a medical test. Whether imaging, laboratory, or other, all medical tests must be:
- Technically reliable
- Clinically valid
- Clinically useful

Because different specialties may use different terms for the same concept, we are highlighting the core characteristics. The core characteristics also apply to different uses of tests, such as diagnosis, prognosis, and monitoring treatment.

Diagnostic tests detect presence or absence of a condition. Surveillance and treatment monitoring are essentially diagnostic tests over a time frame. Surveillance to see whether a condition develops or progresses is a type of detection. Treatment monitoring is also a type of detection because the purpose is to see if treatment is associated with the disappearance, regression, or progression of the condition.

Prognostic tests predict the risk of developing a condition in the future. Tests to predict response to therapy are also prognostic. Response to therapy is a type of condition and can be either a beneficial response or adverse response. The term predictive test is often used to refer to response to therapy. To simplify terms, we use prognostic to refer both to predicting a future condition or to predicting a response to therapy.

Technically Reliable
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

In 2012, the Agency for Healthcare Research and Quality published a comparative effectiveness review of screening for glaucoma. Included were randomized controlled trials (RCTs), quasi-RCTs, observational cohort and case-control studies, and case series with more than 100 participants. The interventions evaluated included ophthalmoscopy, fundus photography or computerized imaging (OCT, retinal tomography, SLP), pachymetry (corneal thickness measurement), perimetry, and tonometry. No evidence was identified that addressed whether an open-angle glaucoma screening program led to a reduction in IOP, less visual impairment, reduction in visual field loss or optic nerve damage, or improvement in patient-reported outcomes. No evidence was identified on harms of a screening program. Over 100 studies were identified on the diagnostic accuracy of screening tests. However, due to the lack of a definitive diagnostic reference standard and heterogeneity in study designs, synthesis of results could not be completed.

A Cochrane review (2015) assessed the diagnostic accuracy of optic nerve head and RNFL imaging for glaucoma. Included were 103 case-control studies and 3 cohort studies (total N=16,260 eyes) that evaluated the accuracy of recent commercial versions of OCT (spectral domain), Heidelberg Retinal Tomograph (HRT) III, or SLP (GDx VCC or ECC) for diagnosing glaucoma. The population was patients referred for suspected glaucoma, typically due to an
elevated IOP, abnormal optic disc appearance, and/or an abnormal visual field identified in primary eye care. Population-based screening studies were excluded. Most comparisons examined different parameters within the 3 tests, and the parameters with the highest diagnostic odds ratio were compared. The 3 tests (OCT, HRT, SLP) had similar diagnostic accuracy. Specificity was close to 95%, while sensitivity was 70%. Because a case-control design with healthy participants and glaucoma patients was used in nearly all studies, concerns were raised about the potential for bias, overestimation of accuracy, and applicability of the findings to clinical practice.

**Clinically Useful**
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

**Direct Evidence**
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

A technology assessment, conducted by Lin et al (2007) for the American Academy of Ophthalmology, reviewed 159 studies published between 2003 and 2006, evaluating optic nerve head and RNFL devices used to diagnose or detect glaucoma progression. The assessment concluded: “The information obtained from imaging devices is useful in clinical practice when analyzed in conjunction with other relevant parameters that define glaucoma diagnosis and progression.” Management changes for patients diagnosed with glaucoma may include the use of IOP-lowering medications, monitoring for glaucoma progression, and potentially surgery to slow the progression of glaucoma.

**Section Summary: Imaging of the Optic Nerve and RNFL**
Numerous studies and systematic reviews have described findings from patients with glaucoma using CSLO, SLP, and OCT. Although the specificity in these studies was high, it is likely that accuracy was overestimated due to the case-control designs used in the studies. The literature and specialty society guidelines have indicated that optic nerve analysis using CSLO, SLP, and OCT are established add-on tests that can be used with other established tests to improve the diagnosis and direct management of patients with glaucoma and those who are glaucoma suspects. Management changes for patients diagnosed with glaucoma may include the use of IOP-lowering medications, monitoring for glaucoma progression, and potentially surgery.

**Evaluation of Ocular Blood Flow**

**Clinical Context and Test Purpose**
The diagnosis and monitoring of optic nerve damage are essential for evaluating the progression of glaucoma and determining appropriate treatment. Measurement of ocular blood flow has been studied as a technique to evaluate patients with glaucoma or suspected glaucoma.

The question addressed in this evidence review is: Do various techniques (e.g., color Doppler imaging [CDI], Doppler Fourier domain OCT, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, retinal functional imager) for assessing ocular blood flow improve diagnosis and monitoring of glaucoma? One potential application is the early detection of normal tension glaucoma (NTG).

The following PICOTS were used to select literature to inform this review.
Patients
The relevant patient populations are patients with glaucoma or suspected glaucoma and are being evaluated for diagnosis and monitoring of glaucoma progression. These tests may have particular utility for NTG.

Interventions
The tests being considered for assessment of the optic nerve and optic nerve layer include CDI, Doppler Fourier domain OCT, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, and retinal functional imager.

Comparators
There is no criterion standard for the diagnosis of glaucoma. The diagnosis of glaucoma is made using a combination of visual field testing, IOP measurements, and optic nerve and RNFL assessment.

Outcomes
Relevant outcomes include the reliability of the test for evaluating ocular blood flow and the association between ocular blood flow parameters and glaucoma progression. Demonstration that the information can be used to improve patient outcomes is essential to determining the utility of a diagnostic technology. Although direct evidence on the impact of the imaging technology from controlled trials would be preferred, in most cases, a chain of evidence is needed to determine whether there is a tight linkage between the technology and improved health outcomes. The outcomes relevant to this evidence review are IOP, loss of vision, and changes in IOP-lowering medications used to treat glaucoma.

Timing
For patients with manifest glaucoma, the relevant period of follow-up is the immediate diagnosis of glaucoma. For patients with suspected glaucoma, longer term follow-up would be needed to detect changes in IOP and loss of vision. Clinical utility might be demonstrated by a change in the management and reduction in glaucoma progression across follow-up.

Setting
Many of these procedures are performed with specialized equipment. While reports of use are longstanding (e.g., Bafa et al [2001]), investigators have commented on the complexity of these parameters and have noted that many of these technologies are not commonly used in clinical settings.

Technically Reliable
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Abegao Pinto et al (2016) reported on the results from the prospective, cross-sectional, case-control, Leuven Eye Study, which included 614 individuals who had primary open-angle glaucoma (n=214), NTG (n=192), ocular hypertension (n=27), suspected glaucoma (n=41), or healthy controls (n=140). The study objective was to identify the blood flow parameters most highly associated with glaucoma using technology commonly available in an ophthalmologist’s office or hospital radiology department. Assessment of ocular blood flow included CDI, retinal oximetry, dynamic contour tonometry, and OCT enhanced-depth imaging of the choroid. The glaucoma group had higher perfusion pressure than controls (p < 0.001), with lower velocities in both central retinal vessels (p < 0.05), and choroidal thickness asymmetries. The NTG group, but
not the primary open-angle glaucoma group, had higher retinal venous saturation than healthy controls \(p=0.005\). There were no significant differences in macular scans. The diagnostic accuracy and clinical utility were not addressed.

Kurysheva et al (2017) compared ocular blood flow with choroidal thickness to determine which had a higher diagnostic value for detecting early glaucoma.\(^{12}\) Thirty-two patients with pre-perimetric glaucoma were matched with 30 control patients. Using OCT, RNFL thickness between groups was found to be comparable; the ganglion cell complex was thicker in the control patients, and there was no significant difference between groups for choroidal foveal volume. Mean blood flow velocity in the vortex veins had the highest area under the receiver operating characteristic curve ROC (1.0) and \(z\)-value (5.35). Diastolic blood flow velocity in the central retinal artery had a diagnostic value of 2.74 and area under the receiver operating characteristic curve of 0.73. The authors concluded that this study suggested a diagnostic benefit in measuring blood flow velocities.

Witkowska et al (2017) investigated blood flow regulation using laser speckle flowgraphy in 27 individuals.\(^{13}\) In this prospective study, the authors specifically looked at mean blur rate blood flow in the optic nerve head and a peripapillary region. First, participants’ blood flow was measured when they were in a sitting position; then, participants were asked to perform an isometric “squatting” exercise for 6 minutes. Compared with baseline (sitting), exercise significantly increased ocular perfusion blood pressure (78.5%), mean blur rate in the tissue of the optic nerve head (18.1%), and mean blur rate in the peripapillary region (21.18\%) \(p<0.001\). Few studies have used laser speckle flowgraphy to study autoregulation of ocular blood flow during a change in blood pressure, and this study is limited to Japanese populations. Despite the lack of literature and limited population, the authors noted laser speckle flowgraphy could be a valuable tool to study the regulation of blood flow in the optic nerve head, particularly in patients suspected of having glaucoma or patients who have glaucoma.

Rusia et al (2011) reported on use of CDI in normal and glaucomatous eyes.\(^{14}\) Using data from other studies, a weighted mean was derived for the peak systolic velocity, end-diastolic velocity, and Pourcelot Resistive Index in the ophthalmic, central retinal, and posterior ciliary arteries. Data from 3061 glaucoma patients and 1072 controls were included. Mean values for glaucomatous eyes were within 1 standard deviation of the values for controls for most CDI parameters. Methodologic differences created interstudy variance in CDI values, complicating the construction of a normative database and limiting its utility. The authors noted that because the mean values for glaucomatous and normal eyes had overlapping ranges, caution should be used when classifying glaucoma status based on a single CDI measurement.

### Table 2. Summary of Key Nonrandomized Study Characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Type</th>
<th>Country</th>
<th>Dates</th>
<th>Participants</th>
<th>Treatment 1</th>
<th>Treatment 2</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurysheva (2017)(^{12})</td>
<td>Prospective</td>
<td>Russia</td>
<td>NR</td>
<td>Patients with pre-perimetric glaucoma ((n=32)) and age-matched controls ((n=30))</td>
<td>Optical coherence tomography</td>
<td></td>
<td>NR</td>
</tr>
<tr>
<td>Witkowska (2017)(^{13})</td>
<td>Prospective</td>
<td>Austria</td>
<td>2015-2016</td>
<td>Healthy subjects ((n=27))</td>
<td>Laser speckle flowgraphy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

POAG: primary open-angle glaucoma; NTG: normal-tension glaucoma; OHT: ocular hypertension; NR: not reported.
### Table 3. Summary of Key Nonrandomized Study Results

<table>
<thead>
<tr>
<th>Study</th>
<th>AUC and Diagnostic Value AUC; p-value</th>
<th>Increase in OPP from Baseline</th>
<th>Increase in MTONH from Baseline</th>
<th>Increase in MTPPR from Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurysheva (2017)12</td>
<td>1.0; &lt;0.0001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M BFV in VV</td>
<td>0.85; 0.0001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M BFV in CRV</td>
<td>0.73; 0.006</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBFV in CRA</td>
<td>0.71; 0.011</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBFV in LSPCAs</td>
<td>78.5±19.8%</td>
<td>18.1±7.7%</td>
<td>21.1±8.3%</td>
<td></td>
</tr>
</tbody>
</table>

AUC: area under the receiver operating characteristic curve; OPP: ocular perfusion pressure; MTONH: mean blur rate in the tissue of the optic nerve head; MTPPR: mean blur rate in the peripapillary region; M BFV: mean blood flow velocity; VV: vortex veins; CRV: central retinal vein; DBFV: diastolic blood flow velocity; CRA: central retinal artery; LSPCA: lateral short posterior ciliary artery.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

The clinical utility of techniques to evaluate ocular blood flow is similar to that for other imaging techniques. The objective is to improve the diagnosis and direct management of patients with glaucoma or suspected glaucoma. Measures of ocular blood flow may have particular utility for the diagnosis and monitoring of NTG.

The only longitudinal study identified is a study by Calvo et al (2012) on the predictive value of retrobulbar blood flow velocities in a prospective series of 262 who were glaucoma suspect.15 At baseline, all participants had normal visual field, increased IOP (mean, 23.56 mm Hg), and glaucomatous optic disc appearance. Blood flow velocities were measured by CDI during the baseline examination, and conversion to glaucoma was assessed at least yearly according to changes observed with CSLO. During the 48-month follow-up, 36 (13.7%) patients developed glaucoma and 226 did not. Twenty (55.5%) of those who developed glaucoma also showed visual field worsening (moderate agreement, κ=0.38). Mean end-diastolic and mean velocity in the ophthalmic artery were significantly reduced at baseline in subjects who developed glaucoma compared with subjects who did not.

### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility. The evidence does not permit any inferences about the utility of ocular blood flow evaluation in the evaluation of glaucoma.

### Section Summary: Evaluation of Ocular Blood Flow

Techniques to measure ocular blood flow or ocular blood velocity are being evaluated for the diagnosis of glaucoma. Data for these techniques remain limited. Current literature focuses on which technologies are most reliably associated with glaucoma. Literature reviews have not identified studies that suggest whether these technologies improve the diagnosis of glaucoma or whether measuring ocular blood flow in patients with glaucoma or suspected glaucoma improves health outcomes.
Summary of Evidence
For individuals who have glaucoma or suspected glaucoma who receive imaging of the optic nerve and RNFL, the evidence includes studies on diagnostic accuracy. Relevant outcomes are test accuracy, symptoms, morbid events, functional outcomes, and medication use. CSLO, SLP, and OCT can be used to evaluate the optic nerve and RNFL in patients with glaucoma and suspected glaucoma. Numerous articles have described findings from patients with known and suspected glaucoma using CSLO, SLP, and OCT. These studies have reported that abnormalities may be detected on these examinations before functional changes are noted. The literature and specialty society guidelines have indicated that optic nerve analysis using CSLO, SLP, and OCT are established add-on tests that may be used to diagnose and manage patients with glaucoma and suspected glaucoma. These results are often considered along with other findings to make diagnostic and therapeutic decisions about glaucoma care, including use of topical medication, monitoring, and surgery to lower IOP. Thus, accurate diagnosis of glaucoma would be expected to reduce the progression of glaucoma. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have glaucoma or suspected glaucoma who receive evaluation of ocular blood flow, the evidence includes association studies. Relevant outcomes are test accuracy, symptoms, morbid events, functional outcomes, and medication use. Techniques to measure ocular blood flow or ocular blood velocity are used to determine appropriate glaucoma treatment options. The data for these techniques remain limited. Literature reviews have not identified studies addressing whether these technologies improve diagnostic accuracy or whether they improve health outcomes in patients with glaucoma. Some have suggested that these parameters may inform understanding of the variability in visual field changes in patients with glaucoma, i.e., they may help explain why patients with similar levels of IOP develop markedly different visual impairments. However, data on use of ocular blood flow, pulsatile ocular blood flow, and/or blood flow velocity are currently lacking. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests from Blue Cross Blue Shield Association, input was received from 1 physician specialty society and 3 academic medical centers in 2009. Most reviewers supported use of confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography in the care of patients with glaucoma and those with suspected glaucoma suspect. Reviewers provided data to demonstrate that this testing is equivalent to expert assessment of optic disc photography for both detecting glaucoma and showing disease progression. Reviewers also commented on favorable aspects of this testing. For example, unlike other glaucoma testing, these tests can be done more easily (e.g., testing does not always need to be done with dilated pupils) and ambient light level may be (is) less critical. In addition, while serial stereophotographs of the optic nerves are considered by many as the criterion standard, they are not always practical, especially for general ophthalmologists. This testing also requires less cooperation from the patient, which can help when evaluating some older patients.

Practice Guidelines and Position Statements
American Academy of Ophthalmology
The American Academy of Ophthalmology issued 2 preferred practice patterns (2015) on primary open-angle glaucoma suspect and primary open-angle glaucoma, both recommending evaluation of the optic nerve and retinal nerve fiber layer (RNFL). The documents stated that “Although they are distinctly different methodologies, stereoscopic disc photographs and computerized images of the nerve are complementary with regard to the
information they provide the clinician who must manage the patient.” The guidelines described 3
types of computer-based imaging devices (confocal scanning laser ophthalmoscopy,
scanning laser polarimetry, optical coherence tomography) currently available for glaucoma,
which are similar in their ability to distinguish glaucoma from controls and noted that “computer-
based digital imaging of the ONH [optic nerve head] and RNFL is routinely used to provide
quantitative information to supplement the clinical examination of the optic nerve…. One
rationale for using computerized imaging is to distinguish glaucomatous damage from eyes
without glaucoma when thinning of the RNFL is measured, thereby facilitating earlier diagnosis
and detection of optic nerve damage”. In addition, the Academy concluded that, as device
technology evolves, the performance of diagnostic imaging devices is expected to improve.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage
determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02178085</td>
<td>Ocular Blood-flow Assessment by Magnetic Resonance Angiography in Glaucoma</td>
<td>62</td>
<td>Sep 2019</td>
</tr>
<tr>
<td>NCT01957267</td>
<td>Longitudinal Observational Study Using Functional and Structural Optical Coherence Tomography to Diagnose and Guide Treatment of Glaucoma</td>
<td>160</td>
<td>Dec 2022</td>
</tr>
</tbody>
</table>

NCT: National Clinical Trial

References

1. Mohindroo C, Ichhpujani P, Kumar S. Current imaging modalities for assessing ocular
   27857490.
2. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Retinal nerve fiber
   analysis for the diagnosis and management of glaucoma. TEC Assessments. 2001;Volume
   16:Tab 13.
3. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Retinal nerve fiber layer
   analysis for the diagnosis and management of glaucoma. TEC Assessments. 2003;Volume
   18:Tab 7.
4. Ervin AM, Boland MV, Myrowitz EH, et al. Screening for Glaucoma: Comparative
   Effectiveness (Comparative Effectiveness Review No. 59). Rockville, MD: Agency for
   Healthcare Research and Quality; 2012.
5. Michelessi M, Lucenteforte E, Oddone F, et al. Optic nerve head and fibre layer imaging
   26618332.
7. Shiga Y, Omodaka K, Kunikata H, et al. Waveform analysis of ocular blood flow and the


**Documentation for Clinical Review**

**Please provide the following documentation (if/when requested):**

- History and physical and/or consultation notes including:
  - Clinical indications/justification of procedure
  - Comprehensive ophthalmologic examination
  - Comorbidities, including vascular disorders
  - Treatment plan
- Diagnostic imaging with interpretation and report results
- Optic nerve analysis outcomes

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**MN/IE**

The following services may be considered medically necessary in certain instances and investigational in others. Services may be considered medically necessary when policy criteria are met. Services may be considered investigational when the policy criteria are not met or
when the code describes application of a product in the position statement that is investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0198T</td>
<td>Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report</td>
</tr>
<tr>
<td></td>
<td>92133</td>
<td>Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve</td>
</tr>
<tr>
<td>HCPCS</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>ICD-10 Procedure</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/29/2015</td>
<td>BCBSA Medical Policy adoption</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>10/01/2016</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>05/01/2017</td>
<td>Policy title change from Ophthalmologic Techniques for Evaluating Glaucoma</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>05/01/2018</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>05/01/2019</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>

**Definitions of Decision Determinations**

**Medically Necessary:** A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.
Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.